α-Tocopherol succinate improves encapsulation and anticancer activity of doxorubicin loaded in solid lipid nanoparticles
Source abstract
Abstract
This work aimed to develop solid lipid nanoparticles (SLN) co-loaded with doxorubicin and α-tocopheryl succinate (TS), a succinic acid ester of α-tocopherol that exhibits anticancer actions, evaluating the influence of TS on drug encapsulation efficiency. The SLN were characterized for size, zeta potential, entrapment efficiency (EE), and drug release. Studies of in vitro anticancer activity were also conducted. The EE was significantly improved from 30 ± 1% to 96 ± 2% for SLN without and with TS at 0.4%, respectively. In contrast, a reduction in particle size from 298 ± 1 to 79 ± 1 nm was observed for SLN without and with TS respectively. The doxorubicin release data show that SLN provide a controlled drug release. The in vitro studies showed higher cytotoxicity for doxorubicin-TS-loaded SLN than for free doxorubicin in breast cancer cells. These findings suggest that TS-doxorubicin-loaded SLN is a promising alternative for the treatment of cancer.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Advancements in Transdermal Drug Delivery · Nanoparticle-Based Drug Delivery · Antioxidant Activity and Oxidative Stress
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (36)
Show source-provided references
1. Doxorubicin: the good, the bad and the ugly effect10.2174/092986709788803312 ↗
2. Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems10.1111/j.2042-7158.2012.01567.x ↗
3. Treatment-related cardiotoxicity in survivors of childhood cancer10.1038/nrclinonc.2013.195 ↗
4. Chemotherapy-enhanced inflammation may lead to the failure of therapy and metastasis10.2147/OTT.S60114 ↗
5. Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment
6. Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection10.1016/j.pcad.2010.06.007 ↗
7. Chemotherapy and/or radiotherapy in combination with surgery for ovarian carcinosarcoma
8. Non-pegylated liposomal doxorubicin in combination with cyclophosphamide or docetaxel as first-line therapy in metastatic breast cancer: a retrospective analysis10.1177/030089160909500402 ↗
9. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial10.1200/JCO.2001.19.6.1707 ↗
10. Tumor delivery of macromolecular drugs based on the EPR effect10.1016/j.addr.2010.03.011 ↗
11. Solid lipid nanoparticles: production, characterization and applications10.1016/S0169-409X(01)00105-3 ↗
12. Solid lipid nanoparticles (SLN) for controlled drug delivery—a review of the state of the art10.1016/S0939-6411(00)00087-4 ↗
13. Solid lipid nanoparticles for parenteral drug delivery10.1016/j.addr.2003.12.002 ↗
14. Cytotoxicity of anticancer drugs incorporated in solid lipid nanoparticles on HT-29 colorectal cancer cell line10.1016/j.ejpb.2004.03.026 ↗
15. Development of solid lipid nanoparticles containing ionically complexed chemotherapeutic drugs and chemosensitizers10.1002/jps.20100 ↗
16. A new polymer–lipid hybrid nanoparticle system increases cytotoxicity of doxorubicin against multidrug-resistant human breast cancer cells10.1007/s11095-006-0282-x ↗
17. Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: pharmacokinetics and tissue distribution after i.v. administration to rats10.1006/phrs.2000.0695 ↗
18. New approach to improve encapsulation and antitumor activity of doxorubicin loaded in solid lipid nanoparticles10.1016/j.ejps.2012.10.025 ↗
19. Alpha tocopheryl succinate, the most effective form of vitamin E for adjuvant cancer treatment: a review10.1080/07315724.2003.10719283 ↗
20. Vitamin E succinate promotes breast cancer tumor dormancy10.1006/jsre.2000.5948 ↗
21. Vitamin E succinate induced apoptosis and enhanced chemosensitivity to paclitaxel in human bladder cancer cells in vitro and in vivo10.1111/j.1349-7006.2009.01362.x ↗
22. Vitamin E succinate suppresses prostate tumor growth by inducing apoptosis10.1002/ijc.21689 ↗
23. Vitamin E succinate induces ceramide-mediated apoptosis in head and neck squamous cell carcinoma in vitro and in vivo10.1158/1078-0432.CCR-07-1811 ↗
24. α-Tocopheryl succinate enhances doxorubicin-induced apoptosis in human gastric cancer cells via promotion of doxorubicin influx and suppression of doxorubicin efflux10.1016/j.canlet.2011.04.001 ↗
25. High-performance liquid chromatographic validated assay of doxorubicin in rat plasma and tissues10.1016/S0378-4347(98)00475-7 ↗
26. In vivo evaluation of a new polymer-lipid hybrid nanoparticle (PLN) formulation of doxorubicin in a murine solid tumor model10.1016/j.ejpb.2006.10.022 ↗
27. Lipid nanoparticles for the delivery of poorly water-soluble drugs10.1111/j.2042-7158.2010.01024.x ↗
28. Drug release from differently structured monoolein/poloxamer nanodispersions studied with differential pulse polarography and ultrafiltration at low pressure10.1002/jps.20808 ↗
29. pH-Dependent doxorubicin release from terpolymer of starch, polymethacrylic acid and polysorbate 80 nanoparticles for overcoming multi-drug resistance in human breast cancer cells10.1016/j.ejpb.2012.09.001 ↗
30. Drug resistance and the solid tumor microenvironment10.1093/jnci/djm135 ↗
31. In-vitro dissolution methods for controlled release parenterals and their applicability to drug-eluting stent testing10.1111/j.2042-7158.2011.01439.x ↗
32. Development of idarubicin and doxorubicin solid lipid nanoparticles to overcome Pgp–mediated multiple drug resistance in Leukemia10.1166/jbn.2009.1021 ↗
33. Novel nanostructured lipid carrier co-loaded with doxorubicin and docosahexaenoic acid demonstrates enhanced in vitro activity and overcomes drug resistance in MCF-7/Adr cells10.1007/s11095-013-1290-2 ↗
34. A novel doxorubicin-mitomycin C co-encapsulated nanoparticle formulation exhibits anti-cancer synergy in multidrug resistant human breast cancer cells10.1007/s10549-008-0271-3 ↗
35. Doxorubicin and MBO-asGCS oligonucleotide loaded lipid nanoparticles overcome multidrug resistance in adriamycin resistant ovarian cancer cells (NCI/ADR-RES)10.1016/j.ijpharm.2012.04.050 ↗
36. Oxidative stability of DHA phenolic ester10.1016/j.foodchem.2014.07.124 ↗